Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Haemophilus influenzae type B vaccine II DEC / 98
Halazepam and its saltsTS I SEP / 98
Halofantrine or its saltsPDL I DEC / 13
Halofuginone or its saltsPDL

For veterinary use.

I MAY / 18
HaloperidolPDL I DEC / 13
Haloprogin III SEP / 98
HalothanePDL I DEC / 13
HaloxazolamTS I JUN / 02
HeminPDL I AUG / 18
Heparin and its salts for topical use III SEP / 98
Heparin and its salts. except for topical use II SEP / 99
Hepatitis A vaccine I FEB / 02
Hepatitis B Adult vaccine I FEB / 02
Hepatitis B Pediatric vaccine II DEC / 98
Hepatitis B immune globulin I FEB / 02
HeptabarbitalC2 I JUN / 02
Hetacillin or its salts or derivativesPDL

For veterinary use.

I DEC / 13
Hetastarch or its derivativesPDL I DEC / 13
Hexachlorophene or its saltsPDL I DEC / 13
Hexacyclonate sodiumPDL I DEC / 13
Hexamethonium or its saltsPDL I DEC / 13
HexethalC2 I JUN / 02
HexobarbitalC2 I JUN / 02
Histamine and its salts except for topical use II SEP / 98
Histrelin or its saltsPDL I DEC / 13
Homatropine and its salts for oral use in concentrations of 2 mg or less per dosage unit II SEP / 98
Homatropine and its salts for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit I SEP / 98
Human insulinD II SEP / 98
Hyaluronic acid and its salts preparations in concentrations of 5% or more II SEP / 98
Hyaluronic acid or its saltsPDL

For veterinary use - when sold or recommended for administration by intra-articular injection to horses.

 

I DEC / 13
Hyaluronidase II SEP / 98
Hydralazine or its saltsPDL I DEC / 13
HydrocodoneN I JUN / 02
Hydrocortisone aceponatePDL

For veterinary use.

I DEC / 13
Hydrocortisone or hydrocortisone acetate

When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age.

I DEC / 14
Hydrocortisone or hydrocortisone acetate.

When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30 g.

I DEC / 14
Hydrocortisone or hydrocortisone acetate..

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing no more than 30 g

III DEC / 14
HydromorphinolN I JUN / 02
HydromorphoneN I JUN / 02
Hydroquinone or its derivativesPDL

When sold in a concentration greater than 2% in preparations for topical use on the skin.

I JUN / 19
Hydroquinone or its derivatives

When sold in a concentration less than or equal to 2% in preparations for topical use on the skin

II JUN / 19
Hydroxocobalamin or its saltsPDL

When recommended as an antidote for cyanide poisoning.

I DEC / 13
Hydroxychloroquine or its saltsPDL I DEC / 13
4- Hydroxycoumarin or its derivativesPDL

Including but not limited to acenocoumarol when sold or recommended as anticoagulants.

I DEC / 13
Hydroxyephedrine and its salts II SEP / 98
HydroxypethidineN I JUN / 02
HydroxyureaPDL I DEC / 13
Hydroxyzine or its salts or derivativesPDL

Including but not limited to cetirizine and hydroxyzine hydrochloride. cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose.

I DEC / 13
Hyoscine and its salts and derivatives [scopolamine] except Hyoscine butylbromide, when recommended for parenteral use II AUG / 16
Hyoscine butylbromidePDL

When recommended for parenteral use.

I AUG / 16
Hyoscyamine and its salts and derivatives except for topical use II SEP / 98

51 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled